Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to oppose confirmation of RFK Jr.

Novo helped to create a new market that should provide over 20% growth in the medium term. At 1.5x PEG I arrive at YE25 price target of $162. Read more on NVO stock here.

Catalent is an attractive buyout target for Novo Holdings, which owns 77% of the voting shares in Novo Nordisk. The deal could boost availability of the drugs because Catalent is the main supplier ...

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to oppose confirmation of RFK Jr.